论文部分内容阅读
目的预测现有乙型肝炎(HBV)多表位疫苗在中国的理论免疫应答率,并做出评价。方法利用“中国多表位疫苗设计的HLA-Ⅰ积累表型频率空间预测系统”计算现有的HBV表位DNA疫苗所涉及的HLA-A、B限制性表位组合在中国人群中的累积表型频率(CPF),得出理论免疫应答率,并绘制CPF预测等值线图,给出评价。结果现有各HBV多表位疫苗对中国人群的理论免疫应答率偏低,仅较多表位组合的疫苗理论免疫应答率高。现有HBV多表位疫苗存在不同方面的问题:大部分此类疫苗对中国人群的理论免疫应答率低;少数此类疫苗理论免疫应答率高,但为较多表位的组合,不符合多表位疫苗设计的原则,并没有用最少的表位组合达到最高的免疫应答率。结论现有的几种主要的HBV多表位疫苗并不能较好地符合中国人群的特点,效果不佳。
Objective To predict and evaluate the theoretical immune response rate of existing hepatitis B (HBV) multi-epitope vaccine in China. Methods HLA-A and B restriction epitopes associated with the current HBV epitope DNA vaccine were calculated using the HLA-I accumulation phenotype frequency space prediction system designed by the Chinese multi-epitope vaccine Cumulative phenotype frequency (CPF), the theoretical immune response rate, and draw CPF prediction contour map, given the evaluation. Results The existing HBV multi-epitope vaccines had a low theoretical immune response rate to the Chinese population, and only the vaccines with more epitope combinations had a higher theoretical immune response rate. Existing HBV polyepitope vaccines have different problems: most of these vaccines have a low theoretical immune response rate to the Chinese population; a few of these vaccines have a high theoretical rate of immune response but do not meet the criteria for more epitope combinations The principle of epitope vaccine design did not achieve the highest immune response rate with the fewest epitope combinations. Conclusion Several existing HBV multi-epitope vaccines do not meet the characteristics of the Chinese population and their effects are not good.